A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.
about
MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxiaWig1 prevents cellular senescence by regulating p21 mRNA decay through control of RISC recruitmentCancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticleRequirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interferenceTumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cellsTherapeutic potential of RNA interference against cancerRNA Interference and Cancer TherapyNovel mechanism of gene transfection by low-energy shock wave.Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo.A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.Advances in Systemic siRNA DeliveryAptamer-targeted cell-specific RNA interferenceSystemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts.Cyclin K and cyclin D1b are oncogenic in myeloma cells.Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.From gene delivery to gene silencing: plasmid DNA-transfecting cationic lipid 1,3-dimyristoylamidopropane-2-[bis(2-dimethylaminoethane)] carbamate efficiently promotes small interfering RNA-induced RNA interference.Efficient and targeted delivery of siRNA in vivo.XB130, a novel adaptor protein, promotes thyroid tumor growth.Experimental study on inhibitory effects of diallyl sulfide on growth and invasion of human osteosarcoma MG-63 cells.RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer.RNAi therapeutics: principles, prospects and challenges.A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors.Endothelial cell-initiated extravasation of cancer cells visualized in zebrafish.Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironmentDevelopment of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.Spatial control of cell gene expression by siRNA gradients in biodegradable hydrogelsHarnessing RNAi nanomedicine for precision therapyAtelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNAProtumoral TSP50 Regulates Macrophage Activities and Polarization via Production of TNF-α and IL-1β, and Activation of the NF-κB Signaling Pathway.Down-regulation of osteopontin attenuates breast tumour progression in vivoThe use of gene therapy in cancer research and treatment.Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expressionsiRNA-mediated inhibition of angiogenesis.A comparative study of three ternary complexes prepared in different mixing orders of siRNA/redox-responsive hyperbranched poly (amido amine)/hyaluronic acidThe therapeutic potential of RNA interference.Individualised cancer therapeutics: dream or reality?Prospects of RNA interference therapy for cancer.The silent treatment: siRNAs as small molecule drugs.
P2860
Q21092263-F2C0311E-274F-427E-BE6F-DE0ECB100B03Q24301358-372ACABC-111B-4A99-B83C-64C4C6F218B7Q24560011-D2979781-F9C6-4791-A191-AC67EF522B8EQ24563464-CE32C051-54FA-44BA-B2F9-F8616A386FDFQ28249223-6BDA5DD0-7110-42DC-B2F8-19645DA7D8D5Q28253746-4DE5AA34-3E3B-4D7C-82AB-3EC0057B7877Q29392204-291CC631-CD93-49E9-AFA9-1A33F6B39638Q30405310-5F799ED9-7E5D-4EDB-86D6-D22A0F6D45D4Q33249303-BA2BDB62-2273-4FDE-A0ED-FA653428C773Q33330928-712C500B-52BB-49FC-A293-F01A4F71C826Q33613316-E669EA06-D791-4C31-88A8-55B177890408Q33717239-74030614-05C4-4EEC-9867-44898DCEF6B4Q33885654-5619D833-0661-4CEA-A98D-0B5DCACF503DQ33895292-609E4F24-6C6E-4CC1-A92C-EA14798ABE75Q33913718-71F7B364-936C-4A7E-BB29-EE69029432E2Q33999330-E03B462B-2F99-4A42-9F9F-5E8504528DFFQ34149828-8627F228-7A43-4D39-9F52-6BC85431950CQ34158435-84AD0C62-D615-495C-A986-3C8CD3374DD7Q34377502-601C0276-A7F9-4EF1-A5E5-1CC70D0D08C5Q34379366-4E6B2D9F-BC8C-4B35-9B11-D98EB4ADA365Q34488806-67D374A8-830B-410D-A4B4-987248865555Q34621268-9E8A3263-053E-4586-9B86-C5358C31FEEDQ34706669-91BF2B6F-6E5C-47FE-9D67-B6789D06E12DQ34777219-EBE39B11-64FD-4E90-B22A-E685E4861F0EQ35052033-47BEDE9E-7211-48CF-9D78-62B6D1E28F9BQ35179033-4BE5D9F3-E2DE-4DF3-8A17-8ED79BC78A86Q35527863-73893C90-B104-46C1-8875-A7AB38A09C20Q35673875-56B527D0-C361-45EE-BA8A-7C2C135ECE24Q35750040-294C09B7-EA3A-4306-B5C1-E9D12C48FDAFQ35764362-C6964378-1919-4A4F-BB62-22625A403982Q35873426-AE1BB381-8CD8-4D9A-9B47-6ACEAC34A170Q35886642-AEBABB30-9B3B-4BFC-B374-83E28FAA215BQ35904008-CBC88C87-E5F1-4F82-957D-50747BA15BDEQ35991706-3D530928-18EC-4FF0-938A-66DF83846E1FQ36099464-80EF4525-BDA5-4C57-9313-91057B2635AAQ36148620-6326E049-4A6F-4371-9667-50909E17DE37Q36237868-12CE12BA-06FD-41E9-8525-A200118BDB03Q36318541-C17DA495-820E-43D0-B846-34F9A14D13AAQ36337922-730033E5-E1D8-4D31-9E44-8ED3758077B4Q36362370-2D703DFC-5D9F-429E-818A-2256E5522421
P2860
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A small interfering RNA target ...... factor as cancer therapeutics.
@en
type
label
A small interfering RNA target ...... factor as cancer therapeutics.
@en
prefLabel
A small interfering RNA target ...... factor as cancer therapeutics.
@en
P2093
P1433
P1476
A small interfering RNA target ...... factor as cancer therapeutics.
@en
P2093
Kenji Kadomatsu
Seiichi Matsuo
Takashi Muramatsu
Yoshifumi Takei
Yukio Yuzawa
P304
P356
10.1158/0008-5472.CAN-03-2682
P407
P577
2004-05-01T00:00:00Z